Obesity, diabetes, adiponectin and the kidney: A podocyte affair

Nephrology Dialysis Transplantation

Volumn 23, Issue 12, 2008, Pages 3767-3770

  Zoccali, Carmine ^a   Mallamaci, Francesca ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Adiponectin; Diabetic nephropathy; Insulin; Obesity; Risk factors

Indexed keywords

ADIPONECTIN;

CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; RISK FACTOR;

ADIPONECTIN; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MICE; OBESITY; PODOCYTES; RENAL INSUFFICIENCY, CHRONIC;

EID: 56749156656     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn517     Document Type: Note

References (35)

1. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555
2. Berghofer A, Pischon T, Reinhold T et al. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008; 8: 200
3. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008; 26: 59-62
4. de Jong PE, van d V Gansevoort RT, Zoccali C. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 2008; 3: 616-623
5. Iseki K. Body mass index and the risk of chronic renal failure: the Asian experience. Contrib Nephrol 2006; 151: 42-56
6. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28
7. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol 2004; 286: F442-F450
8. Coward RJ, Welsh GI, Yang J et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102
9. Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35
10. Chen HM, Liu ZH, Zeng CH et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006; 48: 772-779
11. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634
12. Li JJ, Kwak SJ, Jung DS et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007; S36-S42
13. Ouedraogo R, Wu X, Xu SQ et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55: 1840-1846
14. Longnus SL, Segalen C, Giudicelli J et al. Insulin signalling down-stream of protein kinase B is potentiated by 5′AMP-activated protein kinase in rat hearts in vivo. Diabetologia 2005; 48: 2591-2601
15. Jalovaara K, Santaniemi M, Timonen M et al. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism 2008; 57: 1130-1134
16. Takemura Y, Walsh K, Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238-243
17. Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res 2008; 102: 140-142
18. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866
19. Ohashi K, Iwatani H, Kihara S et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablationmodel of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 1910-1917
20. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
21. Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum? Kidney Int 2007; 71: 1195-1197
22. Zoccali C, Mallamaci F, Panuccio V et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003; S98-S102
23. Bakkaloglu SA, Soylemezoglu O, Buyan N et al. High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse. Pediatr Nephrol 2005; 20: 474-477
24. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606
25. Kollerits B, Fliser D, Heid IM et al. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007; 71: 1279-1286
26. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656
27. Ahima RS. Linking adiponectin to proteinuria. J Clin Invest 2008; 118: 1619-1622
28. Looker HC, Krakoff J, Funahashi T et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010-4017
29. Han SH, Quon MJ, Kim JA et al. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49: 531-538
30. Osei K, Gaillard T, Kaplow J et al. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 2004; 53: 1552-1557
31. Boyle JG, Logan PJ, Ewart MA et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J Biol Chem 2008; 283: 11210-11217
32. Pistrosch F, Herbrig K, Kindel B et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211
33. Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047-2055
34. Dagenais GR, Gerstein HC, Holman R et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31: 1007-1014
35. Mancini MC, Halpern A. Investigational therapies in the treatment of obesity. Expert Opin Invest Drugs 2006; 15: 897-915